A Double-Blind, Placebo-Controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis.

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2016

At a glance

  • Drugs Nerispirdine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Sep 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 02 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top